Key clinical point: Tandem autologous hematopoietic stem cell transplantation and long-term maintenance therapy could extend long-term progression-free survival among some patients with newly diagnosed multiple myeloma.
Major finding: Patients treated with tandem autologous HSCT followed by maintenance lenalidomide had a 6-year progression-free survival rate of 49.4%, compared with 39.7% and 38.6% for patients who underwent single HSCT followed by maintenance therapy, respectively.
Study details: A long-term analysis of the STaMINA phase III trial involving 758 patients with multiple myeloma.
Disclosures: The study was funded by the National Institutes of Health. The investigators disclosed additional relationships with Amgen, Celgene, Novartis, and others. Dr. Richter disclosed affiliations with Takeda, Sanofi, Janssen, and others.
Hari et al. ASCO 2020. Abstract #8506.